Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-09-25

Clinical Trial Update: Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Dysport reconstitution at 1.5 mL vs 2.5 mL for moderate to severe glabellar lines; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Galderma R&D | Conditions: Glabellar Lines, Wrinkles | Phase 4 | Status: COMPLETED | Results posted: 2018-09-25